SCHEMBL13290693

SCHEMBL13290693

O=C(Nc1ccccc1)c1oc2cccnc2c1NC(=O)[C@H]1CC[C@H](N2CCOCC2=O)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.52
▸ KMT2A Q03164 5/20 0.52
▸ HSD17B10 Q99714 4/20 0.45
▸ POLB P06746 2/20 0.45
▸ MAPT P10636 6/20 0.43
▸ KDM4E B2RXH2 3/20 0.43
▸ TSHR P16473 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ HPGD P15428 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ TP53 P04637 3/20 0.42
▸ LMNA P02545 1/20 0.42
▸ DHODH Q02127 1/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ MALT1 Q9UDY8 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.39
▸ MAPK8 P45983 1/20 0.36
▸ MAPK10 P53779 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13290828 0.94 MEN1 (0.45) MEN1KMT2AHSD17B10POLBMAPT
SCHEMBL13290909 0.93 POLB (0.54) MEN1KMT2AHSD17B10POLBMAPT
SCHEMBL2949751 0.93 MEN1 (0.44) MEN1KMT2AHSD17B10POLBMAPT
SCHEMBL2949749 0.93 MEN1 (0.44) MEN1KMT2AHSD17B10POLBMAPT
SCHEMBL2953860 0.93 MAPT (0.49) MEN1KMT2AHSD17B10POLBMAPT
SCHEMBL2953862 0.93 MAPT (0.49) MEN1KMT2AHSD17B10POLBMAPT
SCHEMBL13290694 0.91 MALT1 (0.47) MEN1KMT2AHSD17B10POLBMAPT
SCHEMBL13879426 0.91 MAPT (0.56) MEN1KMT2AHSD17B10POLBMAPT
SCHEMBL13290691 0.89 POLB (0.42) MEN1KMT2AHSD17B10POLBMAPT
SCHEMBL13290900 0.87 MEN1 (0.37) MEN1KMT2AHSD17B10POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 MEN1 1453/4885KMT2A 2033/4885HSD17B10 943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback